Agenus, Inc. – “2015: Poised To Be Another Transformative Year for Agenus”

Agenus, Inc. - "2015: Poised To Be Another Transformative Year for Agenus"

Incyte Corporation (Nasdaq: INCY) and Agenus Inc. (NASDAQ: AGEN) an immunology company developing innovative treatments for cancers and other diseases, today announced the acquisition of key antibody assets of Celexion, LLC, a privately held Cambridge, Mass. It’s best not to wear contact lenses until you have finished treatment and the symptoms have completely gone away. There has been no cure for cancer yet, but the future is looking brighter than ever and today’s treatments are proven more effective than ever before. Christine Klaskin, Vice President of Finance. Further, more than a third of these patients remain alive for more than three years from initial treatment, and more than 80% of these have not progressed. Indeed, one in six Americans between the ages of 14 and 49 have the disease.
Agenus, Inc. - "2015: Poised To Be Another Transformative Year for Agenus"

The company said the safety data from the trial would be analyst by its independent data monitoring committee over the coming months, but as of the last review at the end of May no serious side effects had been identified. Garo Armen on ( The company’s HerpV, a therapeutic vaccine candidate from the recombinant series, which contains QS-21 Stimulon, has been tested in a phase 1 clinical trial for the treatment of genital herpes. The final result was a $102 million dollar loss due to a stronger dollar. QS-21 Stimulon is being studied in 21 vaccine indications, which include GlaxoSmithKline’s Phase III vaccine programs for RTS,S for malaria, MAGE-A3 cancer immunotherapeutic for non-small cell lung cancer and melanoma and HZ/su for shingles. Nasal washes were performed at two, seven and 14 days post inoculation. Agenus’ heat shock protein-based vaccines for cancer and infectious disease have completed Phase 2 studies in glioblastoma multiforme, and in the treatment of herpes simplex viral infection.

Agenus is an immuno-oncology company developing a portfolio of checkpoint modulators (CPMs), heat shock protein peptide-based vaccines and adjuvants. The Company’s QS-21 Stimulon® adjuvant platform is extensively partnered with GlaxoSmithKline and Janssen Sciences Ireland UC and includes several candidates in Phase 2, as well as shingles and malaria vaccines which have both successfully completed Phase 3 clinical trials. is an exclusive, online media publication where publicly and privately held firms alike share insights about their companies and industries. His critically acclaimed essay series The Dark Side of Wheat opens up a new perspective on the universal, human-species specific toxicity of wheat, and is now available for PDF download. During this call, we will review our financial results, as well as provide a corporate update.

You may also like